LPS is a powerful adjuvant, and although LPS-mediated TLR4 signaling has been exquisitely delineated, the in vivo mechanism of how TLR4 responses impact T cell priming is far less clear. Besides costimulation, TNF and type 1 IFN are dominant cytokines released after TLR4 activation and can shape T cell responses, but other downstream factors have not been examined extensively. Depending on context, we show that IFNaR1 blockade resulted in minor to major effects on specific CD4 T cell clonal expansion. To help explain these differences, it was hypothesized that IFNaR1 blockade would inhibit specific T cell migration by reducing chemokine receptor signaling, but specific CD4 T cells from IFNaR1-blocked mice were readily able to migrate in response to specific chemokines. Next, we examined downstream factors and found that type 1 IFN signaling was necessary for chemokine production, even when mice were immunized with specific Ag with LPS and CD134 costimulation. IFNaR1 signaling promoted CXCL9 and CXCL10 synthesis, suggesting that these chemokines might be involved in the LPS and CD134 costimulation response. After immunization, we show that CXCL9 blockade inhibited CD4 T cell accumulation in the liver but also in LNs, even in the presence of elevated serum IFN-b levels. Thus, whereas type 1 IFN might have direct effects on primed CD4 T cells, the downstream chemokines that play a role during migration also impact accumulation. In sum, CXCL9 production is a key benchmark for productive CD4 T cell vaccination strategies.
Introduction
Adjuvanted vaccines have promoted worldwide health through immunization programs [1] . One of the key ingredients in an adjuvanted vaccine is the adjuvant itself [2] . Typically, adjuvants are ligands for pattern recognition receptors that stimulate appropriate levels of inflammation to activate APCs, which prime and costimulate specific CD4 + T cells to help B cells synthesize specific antibodies or stimulate cytotoxic T cells to kill infected cells. Not surprisingly, most data from model systems show that immunization without an adjuvant fails to promote these characteristics of durable humoral and cellular immunity [3, 4] . Thus, a major area of investigation is centered on understanding the immune signals that emanate from adjuvant or costimulatory responses that stimulate and/or sustain specific T cell longevity [5] [6] [7] .
Many adjuvants are ligands for TLR and perhaps the most notable example is the TLR4 ligand bacterial LPS of which its derivative MPL, in combination with alum, is U.S. Food and Drug Administration approved in an adjuvanted human papillomavirus vaccine [8] [9] [10] . Seminal work has shown that TLR4 signaling relies on the MyD88 and TRIF adaptors [11] , and the use of MPL was, at least partially, based on its tendency to signal through TRIF over MyD88 [12, 13] . In our model, we used LPS, as it promotes lasting memory CD4 T cell responses over that with MPL [14] . Important work is investigating less-toxic variants of LPS, manufactured by chemical degradation, synthetic assembly, or genetic modification for their potential use as vaccine adjuvants [15] , but a fundamental understanding of LPS-based CD4 T cell responses is critical for vaccine development as an approach to identify important pathways for T cell survival that might be characteristic of newly developed adjuvants.
Ultimately, TLR4 activation on APCs, similar to the other TLRs, increases the expression of T cell costimulatory ligands [16] and cell maturation [17] and also triggers release of a complex cytokine network [18] . Specifically, LPS adjuvanticity requires dendritic cells for optimal T cell priming [19] , and the TLR4 adaptors largely play nonoverlapping roles in the context of providing queues for T cell differentiation and survivability [20, 21] . The outcome of TLR4 stimulation or the use of LPS during immunization impacts humoral immunity [22] , prevents peripheral T cell tolerance, and promotes long-term T cell memory, as found in different tissues of the body [23] [24] [25] [26] . Perhaps most striking is the addition of costimulation, which potently increases the effectiveness of T cell priming. One example is CD134 (OX40) costimulation, supplied in the form of enforced costimulation with an agonist mAb [27] , and others, such as CD40 and CD137 (4-1BB), also have similar effects [28] [29] [30] . Enforced costimulation is already in use for cancer immunotherapy, validating its importance, and under the right circumstance, could be used to stimulate vaccine development for infectious disease or further improve cancer immunotherapy when combined with TLR ligands [31] [32] [33] [34] . Thus, the triggering of TLR, together with enforced costimulation, provides a powerful combination to prime T cell immunity, and the mechanism behind it is not only unclear but also vitally important to understand so that the pathways leading to adverse events can be separated from the beneficial ones.
A major response to different adjuvant and enforced costimulation platforms includes similar cytokine outputs. As an example, IL-6 and IL-1b are typically produced, and these factors regulate T cell responses, but this commonality largely precludes them from explaining the differences in adjuvant responses. Therefore, probing downstream from the initial cytokine release to find factors that might be different between responses and perhaps exert specialized effects on T cell function is critical to advance vaccine development. Our goal was to study this idea by examining type 1 IFN, which is not as widely produced compared with TNF but has been previously implicated in specific adjuvant responses [35] [36] [37] . Thus, we set out to determine if the potent LPS and anti-CD134 stimulation protocol relied on type 1 IFN or perhaps the downstream mediators in this complex cytokine network.
By tracing T cell and cytokine responses, we found that specific antigen and low levels of LPS with anti-CD134 immunization exerted a strong survival signal on specific CD4 T cells in LN, liver, and lung, whereas type 1 IFN release was rapid and robust. The role of type 1 IFN was context dependent, but nevertheless, T cells without IFNaR were potently handicapped when competing against WT T cells. Our data point to the downstream chemokines that play a role in maintaining specific T cell accumulation and suggest that testing for a precise cytokine and chemokine network might be an important benchmark for the effectiveness of immunization strategies and immunotherapy.
MATERIALS AND METHODS

Mice
C57BL/6 mice and TRIF-deficient, IFNaR1
2/2
, and C57BL/6 congenic CD45.1 mice (Stock Numbers 000664, 005037, 032045, and 002014, respectively) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). TEa CD4 TCR transgenic RAG 2/2 mice, specific to the Ea 52-68 peptide [38, 39] and TCRbd 2/2 mice [40] , were bred at The Jackson Laboratory and in our laboratory. All mice were maintained in the animal facility at the University of Connecticut Health Center under specific pathogen-free conditions and handled in accordance to U.S. National Institutes of Health federal guidelines. [27] . Lymphocytes obtained from pooled pLN (inguinal, axillary, and brachial), spleen, liver, and lung were isolated, similar to our previous approaches [43] . In brief, pLNs and spleen cells were separately crushed through a 100 mm nylon mesh strainer (BD Falcon; Becton Dickinson, Franklin Lakes, NJ, USA), and then spleen cells were further treated with 150 mM ammonium chloride to lyse RBCs. For liver and lung cells, mice were first perfused with PBS containing heparin (Sigma-Aldrich), and then the liver was minced through cell strainers and cells partitioned on a 35% Percoll (GE Healthcare, Piscataway, NJ, USA) gradient. The lungs were cut into small pieces and incubated in 1.3 mM EDTA in BSS without Mg 2+ and Ca 2+ at 37°C for 30 min with agitation, followed by collagenase (Sigma-Aldrich) treatment at 37°C for 20 min with agitation. Lung cells were fractionated on a 44% and 67% Percoll gradient (GE Healthcare) with lymphocytes partitioning at the interface. Lymphocytes from all of the tissues were suspended in BSS (supplemented with HEPES, L-glutamine, penicillin, streptomycin, and gentamicin sulfate). For serum isolation, a few drops of blood were collected from the tail vein, 3 h after immunization, and subjected to the Microtainer tube (BD Life Sciences, Franklin Lakes, NJ, USA) with a clot activator and serum gel separator. After 30-40 min at room temperature, the tube was spun at 8000 g for 1.5 min, and serum was stored at 280°C until analysis.
Immunization and tissue processing
Flow cytometry
For surface staining, ;0. 6 ), respectively. In our second control, we analyzed TEa expansion in C57BL/6 mice that received TEa transfer but no immunization. On d 5, the average of percent TEa cells in spleen and liver of mice was 0.98 6 0.04 and 0.54 6 0.05, respectively, whereas the average of the total number of TEa cells in spleen and liver was 0.02 6 0.003 and 0.001 6 0.0001 (310 6 ), respectively. Data in both of these experiments are derived from 1 experiment, n = 3 mice, represented as means 6 SEM. Overall, this shows that without TEa transfer and immunization, TEa cells in lymphoid (spleen) and nonlymphoid tissue (liver) are very low in numbers, and for optimal expansion, mice need to receive both TEa transfer and immunization.
ELISA, SDS-PAGE, and immunoblotting
A mouse IFN-b ELISA kit was from PBL Assay Science (Piscataway, NJ, USA), mouse CXCL9/MIG DuoSet kit (DY492) or CXCL10/IP-10/CRG-2 DuoSet ELISA kit (DY466) was from R&D Systems (Minneapolis, MN, USA). All ELISAs were performed according to the manufacturer's instructions, and absorbance was determined at 450 nm using an iMark (Bio-Rad Laboratories, Hercules, CA, USA) or CLARIOstar microplate reader (BMG Labtech, Cary, NC, USA). The concentrations were calculated using a standard curve line of best fit on Microplate Manager Software (Bio-Rad Laboratories) or MARS Data Analysis software (BMG Labtech). In brief, for immunoblotting, ;40 mg protein of liver-tissue lysate, suspended in denaturing SDS sample buffer, was resolved on 4-15% SDS-PAGE, transferred onto a 0.2 mm nitrocellulose membrane using a semidry blotting device (Bio-Rad Laboratories), and finally probed with anti-CXCL9 antibody (AF-492-NA; R&D Systems). The membrane was washed, incubated with secondary HRP-conjugated rabbit anti-goat antibody (Santa Cruz Biotechnology, Dallas, TX, USA), and washed, and then band detection was performed using ECL Plus (GE Healthcare Life Sciences). Recombinant CXCL9 (492-MM; R&D Systems) was used as a positive control, and anti-b-actin was used as the loading control (Abcam, Cambridge, MA, USA).
Real-time PCR
On d 5, the liver tissue was harvested, and RNA was extracted from ;30 mg liver tissue using the RNeasy mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer's protocol. The RNA was reverse transcribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories), and a real-time qPCR measurement of cDNA was then performed using iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories) and a CFX96 real-time PCR instrument (Bio-Rad Laboratories). For analysis, gene expression for both the anti-IFNaR1 antibody and IgG-treated group was normalized to b-actin, and the fold change was calculated by subtracting the gene expression of the IgGtreated group from the anti-IFNaR1 group. PCR primers were generated by inputting the National Center for Biotechnology Information accession number for each gene in the primer bank website (https://pga.mgh.harvard. edu/primerbank/) to get a validated forward and reverse primer sequence that was then purchased from Integrated DNA Technologies (Coralville, IA, USA; Supplemental Table 1 ).
Transwell assay
In brief, a 24-well plate containing Transwell inserts (6.5 mm diameter, 5 mm pores; Corning, Lowell, MA, USA) was coated with 50 ml of 10 ng/ml murine fibronectin (Innovative Research, Novi, MI, USA) and incubated for 1 h at 37°C and 5% CO 2 . The solution was removed, and inserts were dried for 2 h at 37°C (without CO 2 ). The pLN lymphocytes were harvested from immunized mice on d 5 or 11 and suspended in CTM (without the FBS), supplemented with 0.5% BSA. The lower chamber of the Transwell was filled with 600 ml of 1,000 ng/ml CXCL9, CXCL10, or CXCL1 in CTM (PeproTech, Rocky Hill, NJ, USA). The lymphocyte suspension (;0.5-1 3 10 6 cells) was then added to the top of the insert and allowed to migrate for 30 min at 37°C and 5% CO 2 . 
Statistical analysis
The data between groups were compared by unpaired, 2-tailed t test by using GraphPad Prism (GraphPad Software, San Diego, CA, USA).
RESULTS
Antigen, LPS, and CD134 costimulation synergize to promote specific T cell clonal expansion and type 1 IFN production
The adjuvant LPS, in combination with CD134 costimulation, promotes robust CD4 and CD8 T cell expansion in response to SEA [29] , as well CD4 T cell memory formation using a model antigen in place of enterotoxin [47] . To study this mechanism, we transferred CD4 TCR transgenic T cells (TEa) into C57BL/6 recipient mice. TEa cells express the TCR-a (Va2) and TCR-b (Vb6) chain that recognizes the Ea 52-68 peptide derived from the a chain of MHC class II protein I-E b and presented on I-A b .
Similar to an immunotherapy strategy, mice are immunized intraperitoneally the next day (d 0) with LPS, anti-CD134 (agonist mAb, OX86), and the Ea peptide. As C57BL/6 mice express I-A b but not I-E b , TEa cells recognize the Ea peptide as a foreign antigen and mount an immune response to it that is detected by staining the TEa cells with CD4 and TCR Va2 and Vb6 on d 11 or 12 following immunization (Fig. 1A) . By d 11 or 12, synergistic CD4 T cell clonal expansion and survival were detected in the liver, which was highest with the combination of peptide with LPS plus CD134 compared with peptide plus CD134 costimulation or LPS (Fig. 1B) . As LPS induces type 1 IFN secretion [48] , we tested if LPS and CD134 together increased type 1 IFN levels compared with either alone with peptide stimulation. Three hours after immunization, serum was collected and examined for IFN-b levels by ELISA (Fig. 1C) . As predicted, CD134 costimulation with LPS induced the highest IFN-b levels, suggesting that IFN-b may play a role in supporting the vaccine T cell response.
In previous work, LPS was shown to promote effector CD8 and CD4 T cell accumulation in nonlymphoid tissues through the TRIF adaptor [43, 45] , whereas lipid A-induced type 1 IFN signaling through TLR4-TRIF-mediated CD4 T cell expansion in the spleen [12, 49] . Similar to our approach, biologics are being combined with TLR agonists for immunotherapy of cancer and infectious disease vaccines [7, 32, 50, 51] , and it was thus reasoned that a key cytokine might be type 1 IFN. To determine if type 1 IFN was involved in the LPS and CD134 costimulation platform, the MAR15A3 mAb, specific to the IFNaR1 subunit receptor [41] , was used to block IFNaR signaling. Although IFNaR signaling is complex, there is a substantial role for p-STAT1 [52] , which in our study, was inhibited in the presence of IFNaR1 blockade ( Fig. 2A) . Based on these data, IFNaR1 was blocked in vivo using MAR15A3 mAb during the immunization approach described in Fig. 1A . As expected, the levels of liver IFN-b, measured by qRT-PCR (Fig. 2B, left) , were decreased, but surprisingly, serum IFN-b levels increased significantly in the blocked mice (Fig. 2B, right) . Thus, the blocking of the type 1 IFNR uncouples a positive-feedback loop previously described [53] , as there is a significant reduction in IFN-b transcription, but IFN-b protein levels increase systemically as a result of blocked receptor-mediated internalization. Hence, these data support the notion that IFNaR1 blockage is effective and might play a role in the LPS plus anti-CD134 immunization approach.
To test this idea, 2 groups of mice were immunized with LPS, anti-CD134 plus specific peptide; 1 group received control IgG and the other anti-IFNaR1 mAb. On d 6 after immunization, the pLNs were examined and showed a significant reduction in expansion or survival of the specific CD4 T cells when IFNaR1 was blocked (Fig. 2C, upper) . This was the case for frequency and cell number, but in liver, there was only a trend largely as a result of an outlier (Fig. 2C, 
lower). To test if host cells required IFNaR1 signaling, IFNaR1
2/2 recipients were used in place of C57BL/6 WT recipients. In this case, there was a slight but significant reduction in percent of antigen-specific CD4 T cells in liver of IFNaR1 2/2 mice on d 5 after immunization, but no difference was found in the pLN and lung (Fig. 2D, upper) . However, the total number of TEa cells was significantly reduced in both liver and lung of IFNaR1 2/2 mice and reduced to almost 50% in the pLN (Fig. 2D, lower) . To understand further how IFNaR signaling in specific CD4 T cells impacts T cell accumulation, we set up an experiment where WT and IFNaR1 2/2 -specific CD4 T cells competed against each other for expansion in the same host. To increase the breadth and robustness of the T cell priming, SEA was used to model an oligoclonal response rather than a single TCR-specific system. SEA potently stimulates TCR Vb3-expressing CD4 T cells [54] and is regarded as a potential cancer therapeutic [55] [56] [57] . Thus, WT CD45.1 + mixed with IFNaR1 2/2 CD4 T cells was transferred into TCR bd 2/2 mice, which prevented competition from endogenous T cells, and then intraperitoneally immunized with SEA, LPS, and CD134 costimulation (Fig. 3A) . On d 7 or 8 after immunization, the IFNaR1 2/2 cells were completely outcompeted by the WT Vb3 T cells (Fig. 3B, left) . This was the case for pLN and liver, and the same was also true for the Vb3 T cells, 15 d after immunization (Fig. 3C, left) . Lastly, the frequency data mirrored total cell numbers ( Fig. 3B and C, right) . Moreover, the nonspecific pLN WT Vb14 T cells were unaffected, but the WT liver Vb14 T cells were increased, likely as a result of organ inflammation (Supplemental Table 2 ), which is similar to other systems where unrelated T cells report to inflamed sites [58] . Thus, specific CD4 T cells deficient in IFNaR1 signaling were profoundly handicapped when competing against WT cells. Nevertheless, this dramatic dependency on IFNaR1 was smaller when the host was IFNaR1 deficient (Fig. 2D ) or in the presence of IFNaR1 blockade by therapy (Fig. 2C) . Overall, IFNaR signaling in both specific T cells, as well nonspecific cells, could promote specific CD4 T cell accumulation, but clearly, antiIFNaR1 therapy could be used to suppress CD4 T cell responses.
We next assessed if IFNaR signaling can influence the effector function of specific CD4 T cells. Analysis of intracellular levels of IFN-g in specific CD4 T cells isolated from the experiment in (Fig. 4A, left) . A similar, but slightly less significant, impact was also seen in the percentage of IFN-g-expressing, nonspecific (Va2 2 Vb6 2 CD4) T cells after PMA + ionomycin stimulation (Fig. 4A, right) . However, the total number of IFN-g-expressing, nonspecific CD4 T cells was significantly reduced in pLNs with anti-IFNaR1 treatment. In liver and lung, IFN-g production from specific or nonspecific CD4 T cells was not impacted greatly with mice from the experiment in Fig. 2D showed that the percentage (Fig. 4B , middle left) and total number (data not shown) of IFN-g-expressing, specific CD4 T cells were significantly reduced in liver after Ea peptide stimulation compared with WT mice. A slightly significant reduction was also seen in the percentage of IFN-g-expressing, specific CD4 T cells in pLN of IFNaR1 2/2 mice after Ea peptide stimulation (Fig. 4B, top left) , whereas the total number of IFN-g-expressing, specific CD4 T cells in pLN trended toward reduction but was not significantly impacted (data not shown). Furthermore, the percent (Fig. 4B , bottom left) and total number (data not shown) of lung IFN-g-expressing, specific CD4 T cells in IFNaR1 2/2 mice were not impacted, but the percentage of IFN-g-expressing, nonspecific CD4 T cells was significantly reduced in pLN and lung after PMA + ionomycin stimulation and also trended toward reduction in the liver (Fig. 4B, right) . The total number of IFN-g-expressing, nonspecific CD4 T cells was also significantly reduced in pLN and lung of IFNaR1 2/2 after PMA + ionomycin stimulation, whereas in liver, they were not significantly impacted (data not shown). Thus, overall, the results from Fig. 4A and B suggest that IFNaR1 signaling in nonspecific cells of the host promotes IFN-g production from both specific as well as nonspecific CD4 T cells.
Downstream mediators of type 1 IFN and their function on effector CD4 T cells
The data above suggest that type 1 IFN blockade might inhibit a downstream pathway in CD4 T cells during this immunization approach. In fact, previous data showed that TRIF signaling in host cells promoted CXCR3 expression on specific CD4 T cells, presumably through IFN-b [43] , but the CXCR3 ligands CXCL9 and CXCL10 were not examined. We examined next whether IFNaR signaling could enhance the expression of CXCR3 on specific CD4 T cells in pLN and liver, similar to TRIF. With the use of cells from experiments in Fig. 2C Fig. 1 ). Anti-IFNaR1 treatment significantly reduced the percent of CXCR3-expressing, nonspecific CD4 T cells but only marginally impacted CXCR3 + -specific CD4 T cells (Supplemental Fig. 1A, upper) . The total number of CXCR3 + -specific and nonspecific CD4 T cells was, however, significantly reduced in the pLN (Supplemental Fig. 1B, upper) . IFNaR1 blockade did The data are representative of 4 independent studies. *P , 0.05; **P , 0.01; ***P , 0.05; ****P , 0.001.
not influence the percent and total number of CXCR3-expressing, specific or nonspecific CD4 T cells in liver (Supplemental Fig. 1A and B, lower), suggesting that IFNaR signaling-induced CXCR3 expression cannot explain how it impacts T cell expansion in both pLN and liver.
As our results in Fig. 4B showed that IFNaR signaling promotes IFN-g production from specific (pLN and liver), as well as nonspecific, CD4 T cells (pLN and lung), it is possible that IFNaR1 signaling induces IFN-g to promote the secretion of chemokines CXCL9 and CXCL10 to influence indirectly CD4 T cell accumulation [59] [60] [61] [62] . Therefore, we sought to determine if these chemokines could impact the migration of antigenspecific CD4 T cells in our vaccine model. To study this, d 6 pLN cells from immunized mice were placed in the upper chamber of a Transwell and various chemokines in the lower, and after 30 min, we determined the percent of specific TEa CD4 T cells that migrated into the lower well (Fig. 5A) . Based on a ratio of TEa CD4 T cell percentage in the bottom over the percent from the top well, it was clear that specific migration was minimal in media alone or with irrelevant chemokine CXCL1 (Fig. 5B) . However, in response to CXCL9 or CXCL10, the ratios were ;3, whether or not the cells were from IFNaR1 blocked mice. Very similar data were generated using d 11 pLN cells (Fig. 5C ), suggesting that CXCR3 was functional, and certainly, the response to CXCL9 and CXCL10 was intact in the presence of IFNaR1 blockade.
As IFN-b-driven chemokine receptor function was not impaired in our migration assay (Fig. 5) , we hypothesized that IFNaR1 blockade inhibited chemokine production rather than receptor expression. With the use of qRT-PCR for CXCL9 and CXCL10, it is clearly shown that liver mRNA expression for both chemokines was significantly inhibited on d 2 and 5 after IFNaR1 blockade (Fig. 6A) . CXCL11 is also a ligand for CXCR3, but C57BL/6 mice do not possess a functional CXCL11 gene [63, 64] . To test this idea further, CXCL9 protein levels were determined by immunoblot using d 5 liver lysates, and similar to the PCR data, there was a consistent reduction in the CXCL9 protein levels after IFNaR1 blockade (Fig. 6B) . Finally, by measuring serum CXCL9 and CXCL10 levels from the experiment in Fig. 2D , we showed a significant reduction in the IFNaR1 2/2 mice but importantly, an increase in IFN-b (Fig. 6C) .
Secondly, we also found significantly reduced serum CXCL9 in immunized TRIF-deficient mice (Fig. 6D, left) , further demonstrating the positive feed-forward loop of IFN-b driving CXCL9. Lastly, we assayed the remaining serum samples from Fig. 1C and found that LPS, but not CD134 costimulation, was critical for CXCL9 production when the TEa CD4 T cells were activated with cognate peptide (Fig. 6D, right) . Overall, these results suggest that LPS-TRIF-induced IFNaR signaling promotes CXCL9 and CXCL10 chemokine expression in our vaccine model. Other reports suggest that CXCL9 is induced by IFN-g rather than type I IFN [59] [60] [61] [62] 65] . Therefore, we analyzed whether LPS-induced IFN-g could promote CXCL9 induction in our vaccine model. TEa recipient mice were treated with anti-IFN-g + mouse IgG antibody, followed by their immunization, and compared with mice treated with antiIFNaR1 + rat IgG antibody, anti-IFN-g + anti-IFNaR1 antibody, or mouse IgG + rat IgG antibody (see Materials and Methods). As shown in Supplemental Fig. 2A , IFNaR1 blockade significantly reduced CXCL9 levels in the serum at 3 h, similar to the IFNaR1 2/2 mice (Fig. 6C) , and IFN-g blockade did not further influence it. However, at 24 h, IFN-g blockade significantly reduced CXCL9 levels in serum, whereas IFNaR1 blockade did not impact it at this time (Supplemental Fig. 2A ). It is important to note that when mice were treated with mouse IgG or antiIFNaR1 antibody, without rat IgG antibody used as a control for IFN-g blockade, CXCL9 levels were not significantly reduced with anti-IFNaR1 treatment compared with control-treated mice (Supplemental Fig. 2B ). This suggests that the inclusion of rat IgG with mouse IgG antibody can result in an additional adjuvant effect inducing higher levels of CXCL9 that were significantly reduced in mice treated with anti-IFNaR1 + rat IgG antibody (Supplemental Fig. 2A) . Nevertheless, our results show that IFNaR signaling can promote CXCL9 induction as early as 3 h, whereas IFN-g induces CXCL9 later at 24 h.
CXCL9 dominates over IFN-b to enhance specific T cell accumulation
To test the hypothesis that CXCL9 and/or CXCL10 play a role in adjuvanting T cell responses, CD4 TEa recipient mice were immunized with Ea peptide plus LPS and CD134 costimulation in the presence of CXCL9 and CXCL10 blockade. Whereas the effects with CXCL10 blockade were trending, perhaps as a result of incomplete inhibition (data not shown), there was nevertheless a statistically significant inhibition of specific CD4 T cell accumulation with CXCL9 blockade (Fig. 7A) . Both the pLN and the liver contained proportionally fewer specific CD4 T cells, and the lung was less impacted but certainly trended toward significant inhibition. Moreover, the absolute number of TEa cells was also significantly reduced in pLN after CXCL9 blockade (Supplemental Table 3 ).
To understand how CXCL9 promotes T cell accumulation in pLN and liver, we analyzed if CXCL9 impacts T cell migration by increasing the number of CXCR3-expressing, specific CD4 T cells. For this, CXCR3 expression on specific T cells was analyzed from experiments in Fig. 7A , and as shown in Fig. 7B , CXCL9 blockade significantly reduced the percent and total number of CXCR3-expressing, specific CD4 T cells in pLN compared with the control-treated mice. However, CXCL9 blockade did not impact the percent or total number of CXCR3-expressing, specific CD4 T cells in liver and lung (data not shown). Thus, migration alone cannot explain how CXCL9 impacts T cell accumulation in these tissues. We next evaluated if CXCL9 impacts T cell accumulation by promoting T cell proliferation. To test this, we analyzed the expression of Ki67 (a nuclear antigen used as a marker of cell proliferation) in specific T cells from experiments done in Fig. 7A . Our results, as shown in Supplemental Fig. 3 , indicate that CXCL9 did not influence the percent or total number of Ki67-expressing, specific CD4 T cells in pLN, liver, or lung. Thus, CXCL9-induced CD4 T cell accumulation does not appear to be a result of increased T cell proliferation. Further understanding of the mechanism of how CXCL9 promotes specific T cell accumulation in both lymphoid (pLN) and nonlymphoid (liver and lung) tissues is important for targeting CXCL9 in T cell vaccination strategies. Collectively, these data show that CXCL9 operates in multiple sites in the immune system and increases the accumulation of stimulated specific CD4 T cells. Mechanistically, it is possible that IFN-b induces CXCL9, and CXCL9 feeds back to increase IFN-b, resulting in T cell accumulation through IFNaR1, which would be supported by the data in Figs. 2 and 3 . Thus, if this postulate were correct, CXCL9 blockade should inhibit IFN-b production. As shown at the time point tested during T cell priming, IFN-b was not reduced as CXCL9 was blocked (Fig. 7C, left) . Hence, specific CD4 T cell accumulation was significantly inhibited when CXCL9 was blocked, even when IFN-b was available. Lastly, CXCL9 blockade actually increased serum CXCL9, as measured by ELISA (Fig. 7C, right) , which might be a function of antibody protection of CXCL9.
In sum, CXCL9 blockade significantly impaired the specific CD4 T cells from accumulating in lymphoid and nonlymphoid tissues, demonstrating a role, not only during migration but also in T cell accumulation.
DISCUSSION
LPS triggering of TLR4 is known to amplify antigen-specific CD4 and CD8 T cell responses [25] , which is potently enhanced by enforcing costimulation [27] . Although roles for proinflammatory cytokines have been suggested [19, [66] [67] [68] , a mechanistic pathway leading to specific T cell survival remains unknown [69] . Here, we tested a role for type 1 IFN in a powerful vaccine and immunotherapy platform consisting of anti-CD134 agonist mAb and low levels of LPS mixed with specific antigenic peptide. 2/2 mice that were immunized with Ea + LPS + anti-CD134 (as in Fig. 2D) , and 3 h later, serum was collected, followed by ELISA analysis of IFN-b, CXCL9, and CXCL10. The data are pooled from 3 independent experiments. *P , 0.05; **P , 0.01; ****P , 0.0001. (D, left) TEa recipient WT or TRIF-deficient mice were intraperitoneally immunized, and 3 h later, CXCL9 serum levels were determined by ELISA. The data are representative of 4 independent experiments. ****P , 0.0001. (Right) The CXCL9 serum levels from the mice in Fig. 1 were analyzed by ELISA. The data are pooled from 2 to 3 experiments. Error bars represent SEM of all experiments in that group.
Depending on the context, Type 1 IFN was important but mainly because it induced production and release of CXCL9 to support specific CD4 T cell accumulation in LN and liver after immunization. Regardless of the IFN-b levels, the optimal adjuvant effect of LPS depended on CXCL9, even with added costimulation. It is proposed that CXCL9 production is an important benchmark for vaccine efficacy and perhaps immunotherapy. In our immunization platform, the TLR4 ligand LPS with CD134 costimulation induced type 1 IFN, but without LPS/CD134 activation, the specific T cells did not survive, which correlated to low levels of type 1 IFN and CXCL9 (Figs. 1 and 6 ). Related to our work, a recent study demonstrated the importance of type 1 IFN signaling in lipid A-induced T cell clonal expansion, wherein the provision of exogenous IFN-b rescued diminished splenic antigenspecific T cell expansion in TRIF-deficient mice [49] . This study also demonstrated that CXCL10 is essential for the lipid A-mediated adjuvant effect on T cells; however, they did not analyze the role of CXCL9 in T cell expansion. Similar to the role of IFN-b, previous results from our lab demonstrated that CD40 activation is capable of rescuing liver CD8 T cells in TRIF-deficient mice after LPS adjuvanticity; however, it could not rescue CD4 T cells to WT levels [43] . Therefore, we postulated that the bypassing of IFNaR signaling during LPS immunization would impact T cell expansion, but it was unclear if this would depend on specific T cells or host cells, such as APCs expressing IFNaR. To study the mechanism of type 1 IFN, we used several approaches.
Analogous to a therapeutic setting, a blocking mAb resulted in a significant reduction in percent and number of specific pLN CD4 T cells, whereas a decrease was trending in the liver (Fig. 2) . In contrast, WT-specific CD4 T cells in IFNaR1 2/2 mice displayed a slightly significant reduction in percent of specific CD4 T cells in liver, but no difference was seen in the pLN and lung (Fig. 2D) . The total number of specific CD4 T cells was, however, significantly reduced in liver and lung and also reduced by ;50% in pLN of IFNaR1 2/2 mice (Materials and Methods).
Thus, IFNaR signaling in both specific T cells as well as nonspecific cells can influence specific CD4 T cell expansion. However, our results in Fig. 3 mice or to all organs or sites of the body. Thus, these 3 approaches exemplify how context is critical in determining the role of immune pathways. Specifically, the competition study showed an impressive difference, and whereas not as apparent in the other systems, the results overall suggest that IFNaR signaling in both specific T cells and nonspecific cells can contribute to CD4 T cell expansion during LPS and CD134 immunization. Ultimately, these data speak to the importance of using multiple systems of neutralization to obtain the range of possibilities that can occur versus those that occur during therapy. Much has been gained with the use of genetically altered murine models, but neutralization studies with blocking reagents might best approximate what occurs in patients treated with biologics.
To understand a mechanism of how type 1 IFN signaling influences T cell responses, we examined several cytokine receptors downstream of TLR and CD134 activation. CXCR3 is induced by stimulation of TLR4 through TRIF signaling and might explain the lack of specific CD4 T cell accumulation in certain organs, such as liver, as CXCR3 is known to mediate T cell migration into liver [70] [71] [72] [73] and is recently shown to promote T cell migration across the tumor vasculature [72] . Our data show that regardless of IFNaR blockade, the specific CD4 T cells responded to the chemokines in a specific fashion (Fig. 5) . Thus, faulty CXCR3-driven migration did not explain the basis for type 1 IFN-mediated responses, suggesting that CXCR3 remained functional, but perhaps its ligands were diminished after IFNaR neutralization. This is important, as the ligands of CXCR3 optimize Th1 responses via dendritic cells [74] , whereas CXCL9 and CXCL10 have been shown to promote T cell-dendritic cell interaction to induce optimal Th1 differentiation in draining LN. In our model, CXCL9 impacted T cell accumulation in pLN, liver, and lung, but it did not influence Th1 differentiation (data not shown). Our immunization model, however, uses a CD134 agonist that is known to induce Th1 differentiation under appropriate conditions [75] [76] [77] , so results between these studies are difficult to compare. Additionally, a recent study suggested that differential expression of CXCL9 and CXCL10 between tissues could promote T cell migration from LN to the liver [78] . Thus, the role of a particular chemokine in promoting T cell response can depend on the infection model and its selective expression in certain tissues. In addition, chemokine CXCL10 has been shown to mediate positioning of CXCR3 + T cells in LNs to assist in CD4 T cell priming during influenza vaccination [79] , suggesting that even in a model of vaccine-derived antigen CXCR3, ligands facilitate Th1 responses. Hence, it was hypothesized that T cell function, attributed to type 1 IFN in response to LPS and CD134 costimulation, might actually occur through CXCR3 stimulation. IFNaR1 blockade significantly reduced CXCL9/10 transcript levels, and IFNaR1
2/2
hosts also contained significantly reduced CXCL9/10 serum levels. Nevertheless, IFNaR1 2/2 hosts contained high amounts of serum IFN-b (Fig. 6 ). This suggests that the transferred specific T cells in the IFNaR1 2/2 hosts had ample access to IFN-b, whereas the host APCs did not, as they were IFNaR1
( Fig. 2D) . Thus, an interesting question arises that asks whether the reduced T cell response in IFNaR1 2/2 mice was a result of minimal levels of CXCL9/10 or because the APCs could not respond to IFN-b. Interestingly, the absence of IFNaR signaling in nonspecific cells of IFNaR1 2/2 mice reduced the IFN-g production by both specific and nonspecific CD4 T cells (Fig. 4) . It has been suggested that CXCL9 production is dependent on IFN-g rather than type I IFN [59] [60] [61] [62] 65] . Likewise, we observed that the blocking of IFN-g reduced CXCL9 levels in serum at 24 h after immunization (Supplemental Fig. 2A) ; however, the blocking of IFNaR signaling also reduced CXCL9 levels in serum but at 3 h. The role of IFNaR signaling in promoting CXCL9 induction has been suggested in few reports [80] [81] [82] ; however, whether it's through a direct or indirect mechanism is unknown. Thus, both type I IFN and IFN-g seem to promote CXCL9 production in our model. When anti-CXCL9 mAb was used to block CXCL9 [42] during immunization, we observed that specific CD4 T cell accumulation was significantly inhibited in LN and liver, even though IFN-b serum levels remained similar to an IgG control group (Fig. 7C,  left) . A question that arises from this study and others is whether IFN-b and CXCL9 play distinct, redundant, or integrated roles. Whereas our data in Fig. 7 do not directly address this issue, the presence of serum IFN-b during CXCL9 blockade suggests that CXCL9 has a distinct function on specific CD4 T cells that IFN-b cannot overcome, at least in our system of immunization. In sum, we conclude that CXCL9 can play a critical role in adjuvant plus enforced costimulation responses, even when IFN-b is present, suggesting that CXCL9 synthesis is a key biomarker for vaccine efficacy.
On the other hand, when there are high IFN-b levels, as seen in IFNaR1 2/2 hosts (Fig. 6C) , the specific T cells have greater access to IFN-b, which functionally results in an increased dose of the cytokine, despite modest amounts of CXCL9. Specifically, a higher than WT level of serum IFN-b might bypass the role of other downstream pathways, making the cytokines appear redundant. This was particularly true in pLNs, where the percent TEa expansion was not significantly reduced in IFNaR1 2/2 mice, unlike that seen in the mice treated with anti-IFNaR1 mAb (Fig.  2C) . Moreover, even though there was a 50% reduction in the total number of TEa cells in pLNs of IFNaR1 2/2 mice, it was still not significant compared with that seen with IFNaR1 antibody blockade (Fig. 2C) . Thus, high levels of type 1 IFN might promote T cell survival when other survival factors are limiting, and IFN-b has been shown to induce T cell survival directly in vitro [83] . Likewise, IFN-b stimulates dendritic cells [84] , but IFNaR was not required for dendritic cell maturation after LPS treatment, but rather, a TLR4 TRIF-based MAPK-intrinsic signal was critical [85] . Likewise, we previously observed a potent LPS adjuvant effect on LN T cells in TRIF-deficient mice, even though liver responses were impaired [43] . Thus, our platform of low levels of LPS administration can prime dendritic cells void of IFNaR signaling, whereas the enforcement of CD134 costimulation on specific CD4 T cells provides a tool to enhance CD4 T cell priming.
Our data show that specific CD4 T cells were impaired in their ability to accumulate in LN or liver during CXCL9 blockade. We did not analyze if CXCL9 and CXCL10 were differentially expressed in pLN and liver to influence T cells between these tissues, as shown in a previous report [78] ; however, the blocking of CXCL9 reduced T cell accumulation in both pLN and liver, whereas CXCL10 blockade also partially reduced CD4 T cell accumulation, although not statistically significant (data not shown). Moreover, CXCL9 blockade reduced the accumulation of CXCR3 + -specific CD4 T cells in the pLN (Fig. 7B) but not in the liver and lung (data not shown), suggesting that CXCL9 may work through mechanisms other than migration to promote T cell accumulation. Thus, it will be important to test whether CXCL9 breaks activation-induced cell death directly in T cells, perhaps by enhancing interactions with dendritic cells [74] . A major challenge in this regard will be to detect dead-specific T cells in vivo that have not bound CXCL9. The other possibility is that CXCL9 enhances cell-cycle progression, leading to greater proliferation, but we found no significant difference in Ki67 staining on d 6, with or without CXCL9 blockade (Supplemental Fig. 3 ). However, our study does demonstrate that CXCL9 promotes CD4 T cell accumulation, substantially adding to the idea that CXCL9 facilitates memory responses by facilitating positioning of central memory CD8 T cells with dendritic cells in LN [80, 86] .
Therefore, CXCL9 has pleiotropic functions, and the understanding of its cellular source, timing of release, and the cells that it targets will add greatly to controlling cellular immunity for biomedical benefit. In particular, CXCL9 release might be especially important in vaccine adjuvant development and also in assessing enforced costimulation protocols for immunotherapy.
